In vivo measurement of phosphorous markers of disease

Disease Markers

Volumn 19, Issue 2-3, 2004, Pages 49-68

  Arias Mendoza, Fernando ^a,c   Brown, Truman R ^a,b  

^a Och Spine at New York Presbyterian Hospitals   (United States)

^b Neurological Institute Basement ^*  (United States)

^c NEUROLOGICAL INSTITUTE   (United States)

Author keywords

31P MR spectroscopy; Chemical shift imaging; Chronic lymphocytic leukemia; In vivo metabolism; Mitochondrial cytopathy; Neuromuscular disease; Non Hodgkin's lymphoma; Schizophrenia

Indexed keywords

BIOLOGICAL MARKER; CREATINE PHOSPHATE; NEUROLEPTIC AGENT; PHOSPHOLIPID; UBIDECARENONE;

BIOENERGY; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; CORRELATION ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DIFFERENTIAL DIAGNOSIS; DISEASE MARKER; DISORDERS OF MITOCHONDRIAL FUNCTIONS; FOLLOW UP; HUMAN; NEUROMUSCULAR DISEASE; NONHODGKIN LYMPHOMA; NUCLEAR OVERHAUSER EFFECT; PHOSPHOLIPID METABOLISM; PHOSPHORUS NUCLEAR MAGNETIC RESONANCE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN LOCALIZATION; REVIEW; SCHIZOPHRENIA; SIGNAL NOISE RATIO; THREE DIMENSIONAL IMAGING; TISSUE DISTRIBUTION; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 1942500213     PISSN: 02780240     EISSN: None     Source Type: Journal    
DOI: 10.1155/2004/419095     Document Type: Review

References (232)

1. S.R. Williams and D.G. Gadian, Tissue metabolism studied in vivo by nuclear magnetic resonance, Q J Exp Physiol 71(3) (1986), 335-360.
2. P.A. Bottomley, Spatial localization in NMR spectroscopy in vivo, Ann N Y Acad Sci 508 (1987), 333-348.
3. T.R. Brown, B.M. Kincaid and K. Ugurbil, NMR chemical shift imaging in three dimensions, Proc Natl Acad Sci USA 79(11) (1982), 3523-3526.
4. H.S. Bachelard, D.W. Cox and P.G. Morris, Nuclear magnetic resonance as a tool to study brain metabolism, Gerontology 33(3-4) (1987), 235-246.
5. S.E. Franks, M.R. Smith and F. Arias-Mendoza, et al., Phosphomonoester concentrations differ between chronic lymphocytic leukemia cells and normal human lymphocytes, Leuk Res 26(10) (2002), 919-926.
6. 31P NMR spectra of the human brain in vivo, NMR Biomed 7(5) (1994), 237-242.
7. 31P NMR, Magn Reson Imaging 6(2) (1988), 135-142.
8. 31P chemical-shift imaging measurements at 1.5 T, Proc Natl Acad Sci USA 88(15) (1991), 6810-6814.
9. T.R. Brown, Practical applications of chemical shift imaging, NMR Biomed 5(5) (1992), 238-243.
10. D.B. Vigneron, S.J. Nelson and J. Murphy-Boesch, et al., Chemical shift imaging of human brain: axial, sagittal, and coronal P-31 metabolite images, Radiology 177(3) (1990), 643-649.
11. 31P MR spectroscopy study, in: High power gradient MR-imaging, advances in MRI II, M. Oudkerk and R.R. Edelman, eds, Berlin, Vienna: Blackwell Wissenschafts-Verlag, GmbH; 1997, pp. 257-262.
12. 31P chemical shift imaging of the human brain in normal volunteers, NMR Biomed 6(3) (1993), 173-180.
13. O. Gonen, A. Mohebbi, R. Stoyanova and T.R. Brown, In vivo phosphorus polarization transfer and decoupling from protons in three-dimensional localized nuclear magnetic resonance spectroscopy of human brain, Magn Reson Med 37(2) (1997), 301-306.
14. 1H chemical-shift-imaging spectroscopy, J Magn Reson B 108(3) (1995), 213-219.
15. 1H-decoupled phosphorus chemical shift imaging, NMR Biomed 9(3) (1996), 105-113.
16. O. Gonen, J. Murphy-Boesch and R. Srinivasan, et al., Simultaneous and interleaved multinuclear chemical-shift imaging, a method for concurrent, localized spectroscopy, J Magn Reson B 104(1) (1994), 26-33.
17. 31P in vivo chemical shift imaging of human brain, Magn Reson Med 32(1) (1994), 104-109.
18. J. Murphy-Boesch, H. Jiang, R. Stoyanova and T.R. Brown, Quantification of phosphorus metabolites from chemical shift imaging spectra with corrections for point spread effects and B1 inhomogeneity, Magn Reson Med 39(3) (1998), 429-438.
19. F. Arias-Mendoza, M.R. Smith and T.R. Brown, Predicting treatment response in non-Hodgkin's lymphoma from pretreatment tumor content of phosphoethanolamine plus phosphocholine, Acad Radiol (2004), in press.
20. J.R. Griffiths, A.R. Tate, F.A. Howe and M. Stubbs, Magnetic Resonance Spectroscopy of cancer-practicalities of multi-centre trials and early results in non-Hodgkin's lymphoma, Eur J Cancer 38(16) (2002), 2085.
21. 31P MRS of the head and neck region, Magn Reson Imaging 19(5) (2001), 755-759.
22. 31P NMR spectra localized by three-dimensional chemical shift imaging, NMR Biomed 9(4) (1996), 141-155.
23. D.J. Taylor, M. Crowe, P.J. Bore, P. Styles, D.L. Arnold and G.K. Radda, Examination of the energetics of aging skeletal muscle using nuclear magnetic resonance, Gerontology 30(1) (1984), 2-7.
24. 31P-NMR in human muscle: transient patterns with exercise, J Appl Physiol 59(1) (1985), 101-104.
25. W.R. Inch, B. Serebrin, A.W. Taylor and R.T. Thompson, Exercise muscle metabolism measured by magnetic resonance spectroscopy, Can J Appl Sport Sci 11(2) (1986), 60-65.
26. D.J. Taylor, P. Styles and P.M. Matthews, et al., Energetics of human muscle: exercise-induced ATP depletion, Magn Reson Med 3(1) (1986), 44-54.
27. A.A. Sapega, D.P. Sokolow, T.J. Graham and B. Chance, Phosphorus nuclear magnetic resonance: a non-invasive technique for the study of muscle bioenergetics during exercise, Med Sci Sports Exerc 19(4) (1987), 410-420.
28. C.A. Boicelli, A.M. Baldassarri, C. Borsetto and F. Conconi, An approach to noninvasive fiber type determination by NMR, Int J Sports Med 10(1) (1989), 53-54.
29. 31P NMR saturation transfer, Magn Reson Med 9(1) (1989), 39-52.
30. 31P-NMR spectroscopy and the metabolic properties of different muscle fibers, J Appl Physiol 68(2) (1990), 644-649.
31. D. Bendahan, S. Confort-Gouny, G. Kozak-Reiss and P.J. Cozzone, Heterogeneity of metabolic response to muscular exercise in humans. New criteria of invariance denned by in vivo phosphorus-31 NMR spectroscopy, FEBS Lett 272(1-2) (1990), 155-158.
32. 31P-MR spectroscopy study in humans, Biochem Biophys Res Commun 178(3) (1991), 871-877.
33. 31P-MR spectroscopy study, Biochem Biophys Res Commun 176(3) (1991), 1204-1209.
34. 31P-chemical shift imaging of intramuscular heterogeneity in exercising human forearm muscle, Am J Physiol 263(2 Pt 1) (1992), C357-C364.
35. G.K. Radda, Control, bioenergetics, and adaptation in health and disease: noninvasive biochemistry from nuclear magnetic resonance, Faseb J 6(12) (1992), 3032-3038.
36. 31P MRS. The role of pH in the evaluation of phosphocreatine and inorganic phosphate recoveries from exercise, NMR Biomed 6(4) (1993), 248-253.
37. G.J. Kemp, D.J. Taylor, P. Styles and G.K. Radda, The production, buffering and efflux of protons in human skeletal muscle during exercise and recovery, NMR Biomed 6(1) (1993), 73-83.
38. G.J. Kemp, D.J. Taylor and G.K. Radda, Control of phosphocreatine resynthesis during recovery from exercise in human skeletal muscle, NMR Biomed 6(1) (1993), 66-72.
39. 31P magnetic resonance spectroscopy, Magn Reson Med 31(3) (1994), 248-258.
40. S. Kuno, H. Takahashi and K. Fujimoto, et al., Muscle metabolism during exercise using phosphorus-31 nuclear magnetic resonance spectroscopy in adolescents, Eur J Appl Physiol Occup Physiol 70(4) (1995), 301-304.
41. 31P magnetic resonance spectroscopy of the Sherpa heart: a phosphocreatine/adenosine triphosphate signature of metabolic defense against hypobaric hypoxia, Proc Natl Acad Sci USA 93(3) (1993), 1215-1220.
42. G.K. Radda, Control of energy metabolism during muscle contraction, Diabetes 45(1) (1996), S88-S92.
43. T.W. Ryschon, D.L. Rosenstein, D.R. Rubinow, J.E. Niemela, R.J. Elin and R.S. Balaban, Relationship between skeletal muscle intracellular ionized magnesium and measurements of blood magnesium, J Lab Clin Med 127(2) (1996), 207-213.
44. 31P magnetic resonance spectroscopy measurements during ischemic exercise in vivo, Magma 4(3-4) (1996), 151-155.
45. K.M. Ward, S.S. Rajan, M. Wysong, D. Radulovic and D.J. Clauw, Phosphorus nuclear magnetic resonance spectroscopy: in vivo magnesium measurements in the skeletal muscle of normal subjects, Magn Reson Med 36(3) (1996), 475-480.
46. 31P MRS of the soleus and gastrocnemius in Sherpas during graded calf muscle exercise, Am J Physiol 273(3 Pt 2) (1997), R999-R1007.
47. K.E. Conley, M.L. Blei, T.L. Richards, M.J. Kushmerick and S.A. Jubrias, Activation of glycolysis in human muscle in vivo, Am J Physiol 273(1 Pt 1) (1997), C306-C315.
48. J. Mizrahi, D. Seelenfreund, E. Isakov and Z. Susak, Predicted and measured muscle forces after recoveries of differing durations following fatigue in functional electrical stimulation, Artif Organs 21(3) (1997), 236-239.
49. 31P NMR studies of glucose transport in human skeletal muscle, Proc Natl Acad Sci USA 95(3) (1998), 1313-1318.
50. 31P magnetic resonance spectroscopy during long periods of exercise and recovery, Eur J Oral Sci 106(1) (1998), 552-558.
51. 31P MRS, Magn Reson Med 30(5) (1993), 552-558.
52. A.A. Sapega, D.P. Sokolow, T.J. Graham and B. Chance, Phosphorus nuclear magnetic resonance: a non-invasive technique for the study of muscle bioenergetics during exercise, Med Sci Sports Exerc 25(6) (1993), 656-666.
53. 31P NMR study in the human skeletal muscle, Biochem Biophys Res Commun 225(1) (1996), 191-194.
54. R.D. Oberhaensli, G.J. Galloway, D.J. Taylor, P.J. Bore and G.K. Radda, Assessment of human liver metabolism by phosphorus-31 magnetic resonance spectroscopy, Br J Radiol 59(703) (1986), 695-699.
55. 31P nuclear magnetic resonance spectra of normal human liver: towards biochemical pathology in vivo, Clin Sci (Lond) 83(2) (1992), 183-190.
56. B. Ross, D. Freeman and L. Chan, Contributions of nuclear magnetic resonance to renal biochemistry, Kidney Int 29(1) (1986), 131-141.
57. D.P. Younkin, M. Delivoria-Papadopoulos and J.C. Leonard, et al., Unique aspects of human newborn cerebral metabolism evaluated with phosphorus nuclear magnetic resonance spectroscopy, Ann Neurol 16(5) (1984), 581-586.
58. 31P NMR, Magn Reson Med 7(3) (1988), 319-336.
59. 31P NMR in vivo, NMR Biomed 5(2) (1992), 53-58.
60. W. Hemmer and T. Wallimann, Functional aspects of creatine kinase in brain, Dev Neurosci 15(3-5) (1993), 249-260.
61. 31P magnetic resonance spectroscopy study in vivo, Pediatr Res 35(4 Pt 1) (1994), 431-435.
62. E.F. Jackson and C.A. Meyers, Introduction to hippocampal spectroscopy, Neuroimaging Clin N Am 7(1) (1997), 143-154.
63. W.M. Chew and H. Hricak, Phosphorus-31 MRS of human testicular function and viability, Invest Radiol 24(12) (1989), 997-1000.
64. 31P magnetic resonance spectroscopy, NMR Biomed 2(4) (1989), 172-178.
65. 31P spectroscopy of skin: potentially a powerful tool for noninvasive study of metabolism in a cutaneous tissue, J Dermatol Surg Oncol 15(11) (1989), 1207-1211.
66. 31P NMR studies of human skin using a modified zig-zag surface coil, NMR Biomed 9(5) (1996), 195-200.
67. P.A. Bottomley, C.J. Hardy and P.B. Roemer, Phosphate metabolite imaging and concentration measurements in human heart by nuclear magnetic resonance, Magn Reson Med 14(3) (1990), 425-434.
68. S. Kuno, T. Ogawa, S. Katsuta and Y. Itai, In vivo human myocardial metabolism during aerobic exercise by phosphorus-31 nuclear magnetic resonance spectroscopy, Eur J Appl Physiol Occup Physiol 69(6) (1994), 488-491.
69. C.J. Twelves, M. Lowry and D.A. Porter, et al., Phosphorus-31 metabolism of human breast-an in vivo magnetic resonance spectroscopic study at 1.5 Tesla, Br J Radiol 67(793) (1994), 36-45.
70. T. Steingrimsdottir, A. Ericsson, A. Franck, A. Waldenstrom, U. Ulmsten and G. Ronquist, Human uterine smooth muscle exhibits a very low phosphocreatine/ATP ratio as assessed by in vitro and in vivo measurements, Eur J Clin Invest 27(9) (1997), 743-749.
71. 31P- nuclear magnetic resonance spectroscopy of blood: a species comparison, J Cardiovasc Magn Reson 2(2) (2000), 143-149.
72. 31P-magnetic resonance spectroscopy and MRI study, Brain 125(Pt 7) (2002), 1635-1645.
73. 31P NMR spectroscopy, Metabolism 34(8) (1985), 737-740.
74. 31P-NMR spectroscopy study, J Neurol Sci 119(1) (1993), 65-73.
75. 31P MR spectroscopy, Radiat Med 13(2) (1995), 63-65.
76. 31P magnetic resonance spectroscopy study, Brain 122(Pt 1) (1999), 121-130.
77. 31P nuclear magnetic resonance spectroscopy: noninvasive biochemical analysis of the ischemic extremity, J Vasc Surg 3(3) (1986), 411-420.
78. 31P-magnetic resonance spectroscopy, Brain 121(Pt 11) (1998), 2119-2126.
79. P. Martinelli, C. Scaglione, R. Lodi, S. Iotti and B. Barbiroli, Deficit of brain and skeletal muscle bioenergetics in progressive supranuclear palsy shown in vivo by phosphorus magnetic resonance spectroscopy, Mov Disord 15(5) (2000), 889-893.
80. 31P-magnetic resonance spectroscopy, Anesthesiology 78(5) (1993), 848-855.
81. 31P magnetic resonance spectroscopy (MRS) of tender points in patients with primary fibromyalgia syndrome, Rheumatol Int 11(2) (1991), 51-54.
82. 31P magnetic resonance spectroscopy, Dermatology 186(3) (1993), 170-175.
83. 10 treatment in retinitis pigmentosa, Mol Aspects Med 15 (1994), s221-s230.
84. 31P magnetic resonance spectroscopy study of mitochondrial function in skeletal muscle of patients with Parkinson's disease, J Neurol Sci 125(1) (1994), 77-81.
85. Z. Argov, W.J. Bank, J. Maris and B. Chance, Muscle energy metabolism in McArdle's syndrome by in vivo phosphorus magnetic resonance spectroscopy, Neurology 37(11) (1987), 1720-1724.
86. C. Salerno, S. Iotti, R. Lodi, C. Crifo and B. Barbiroli, Failure of muscle energy metabolism in a patient with adenylosuccinate lyase deficiency. An in vivo study by phosphorus NMR spectroscopy, Biochim Biophys Acta 1360(3) (1997), 271-276.
87. R. Lodi, R. Rinaldi and A. Gaddi, et al., Brain and skeletal muscle bioenergetic failure in familial hypobetalipoproteinaemia, J Neurol Neurosurg Psychiatry 62(6) (1997), 574-580.
88. N.G. Kennaway, Defects in the cytochrome bcl complex in mitochondrial diseases, J Bioenerg Biomembr 20(3) (1988), 325-352.
89. 31P magnetic resonance spectroscopy in nonaffected carriers of 11778 mtDNA mutation, Neurology 45(7) (1995), 1364-1369.
90. 31P-magnetic resonance spectroscopy in NARP syndrome, J Neurol Neurosurg Psychiatry 57(12) (1994), 1492-1496.
91. 31P-MR spectroscopy indicating a multisystem mitochondrial defect, J Neurol Sci 137(1) (1996), 20-27.
92. R. Massa, R. Lodi and B. Barbiroli, et al., Partial block of glycolysis in late-onset phosphofructokinase deficiency myopathy, Acta Neuropathol (Berl) 91(3) (1996), 322-329.
93. 31P-MRS study, J Neurol Sci 148(1) (1997), 25-31.
94. 31P magnetic resonance spectroscopy, Ann Neurol 42(4) (1997), 573-579.
95. R. Lodi, V. Carelli and P. Cortelli, et al., Phosphorus MR spectroscopy shows a tissue specific in vivo distribution of biochemical expression of the G3460A mutation in Leber's hereditary optic neuropathy, J Neurol Neurosurg Psychiatry 72(6) (2002), 805-807.
96. C. Marsac, D. Stansbie and G. Bonne, et al., Defect in the lipoyl-bearing protein X subunit of the pyruvate dehydrogenase complex in two patients with encephalomyelopathy, J Pediatr 123(6) (1993), 915-920.
97. 31P-MRS in a patient with mitochondrial cytopathy, J Neurol 242(7) (1995), 472-477.
98. 10 improves mitochondrial respiration in patients with mitochondrial cytopathies. An in vivo study on brain and skeletal muscle by phosphorous magnetic resonance spectroscopy, Cell Mol Biol (Noisy-le-grand) 43(5) (1997), 741-749.
99. 31P-MR spectroscopy in patients with mitochondrial cytopathies, Biofactors 9(2-4) (1999), 253-260.
100. Z. Argov, P.F. Renshaw, B. Boden, A. Winokur and W.J. Bank, Effects of thyroid hormones on skeletal muscle bioenergetics. In vivo phosphorus-31 magnetic resonance spectroscopy study of humans and rats, J Clin Invest 81(6) (1988), 1695-1701.
101. M. Erkintalo, D. Bendahan, J.P. Mattei, C. Fabreguettes, P. Vague and P.J. Cozzone, Reduced metabolic efficiency of skeletal muscle energetics in hyperthyroid patients evidenced quantitatively by in vivo phosphorus-31 magnetic resonance spectroscopy, Metabolism 47(7) (1998), 769-776.
102. D.J. Taylor, S.W. Coppack and T.A. Cadoux-Hudson, et al., Effect of insulin on intracellular pH and phosphate metabolism in human skeletal muscle in vivo, Clin Sci (Lond) 81(1) (1991), 123-128.
103. 31P-MRS study, Med Sci Sports Exerc 24(4) (1992), 420-425.
104. 31P nuclear magnetic resonance spectroscopy, Chest 102(6) (1992), 1716-1722.
105. 31P magnetic resonance spectroscopy investigation of skeletal muscle metabolism in uraemic patients, Nephron 65(2) (1993), 222-226.
106. 31P-NMR, In Vivo 10(4) (1996), 429-433.
107. 31P NMR spectroscopy, Ann Neurol 20(4) (1986), 513-519.
108. 31P nuclear magnetic resonance measurement of chronic changes in cerebral metabolites following neonatal intraventricular hemorrhage, Pediatrics 82(3) (1988), 331-336.
109. N.M. Ramadan, H. Halvorson, A. Vande-Linde, S.R. Levine, J.A. Helpern and K.M. Welch, Low brain magnesium in migraine, Headache 29(9) (1989), 590-593.
110. 31P magnetic resonance spectroscopy interictal study, Pediatr Res 42(6) (1997), 866-871.
111. T.A. Cadoux-Hudson, D. Wade and D.J. Taylor, et al., Persistent metabolic sequelae of severe head injury in humans in vivo, Acta Neurochir (Wien) 104(1-2) (1990), 1-7.
112. R.H. Griffey, M.S. Brown, A.D. Bankhurst, R.R. Sibbitt and W.L. Sibbitt, Jr. Depletion of high-energy phosphates in the central nervous system of patients with systemic lupus erythematosus, as determined by phosphorus-31 nuclear magnetic resonance spectroscopy, Arthritis Rheum 33(6) (1990), 827-833.
113. 31P spectroscopic imaging, Neuroradiology 32(1) (1990), 43-46.
114. 1H spectroscopic imaging, Ann Neurol 36(2) (1994), 157-165.
115. S.D. Taylor-Robinson, C. Buckley, K.K. Changani, H.J. Hodgson and J.D. Bell, Cerebral proton and phosphorus-31 magnetic resonance spectroscopy in patients with subclinical hepatic encephalopathy, Liver 19(5) (1999), 389-398.
116. K.P. Braun, W.P. Vandertop, R.H. Gooskens, K.A. Tulleken and K. Nicolay, NMR spectroscopic evaluation of cerebral metabolism in hydrocephalus: a review, Neurol Res 22(1) (2000), 51-64.
117. C. Antozzi, S. Franceschetti and G. Filippini, et al., Epilepsia partialis continua associated with NADH-coenzyme Q reductase deficiency, J Neurol Sci 129(2) (1995), 152-161.
118. P. Montagna, R. Lodi and P. Cortelli, et al., Phosphorus magnetic resonance spectroscopy in cluster headache, Neurology 48(1) (1997), 113-118.
119. 31P MR spectroscopy in 28 patients with mitochondrial cytopathies, J Cereb Blood Flow Metab 13(3) (1993), 469-474.
120. B. Barbiroli, S. Iotti and P. Cortelli, et al., Low brain intracellular free magnesium in mitochondrial cytopathies, J Cereb Blood Flow Metab 19(5) (1999), 528-532.
121. 31P magnetic resonance chemical shift imaging, Acta Psychiatr Scand 86(6) (1992), 455-462.
122. 31P nuclear magnetic resonance spectroscopy: neurodevelopment and schizophrenia, Schizophr Bull 19(1) (1993), 35-53.
123. R.F. Deicken, G. Calabrese and E.L. Merrin, et al., 31phosphorus magnetic resonance spectroscopy of the frontal and parietal lobes in chronic schizophrenia, Biol Psychiatry 36(8) (1994), 503-510.
124. R.F. Deicken, G. Calabrese, E.L. Merrin, S. Vinogradov, G. Fein and M.W. Weiner, Asymmetry of temporal lobe phosphorous metabolism in schizophrenia: a 31phosphorous magnetic resonance spectroscopic imaging study, Biol Psychiatry 38(5) (1995), 279-286.
125. R.F. Deicken, G. Calabrese, E.L. Merrin, G. Fein and M.W. Weiner, Basal ganglia phosphorous metabolism in chronic schizophrenia, Am J Psychiatry 152(1) (1995), 126-129.
126. 31P magnetic resonance spectroscopy studies in schizophrenia, Prostaglandins Leukot Essent Fatty Acids 55(1-2) (1996), 115-118.
127. 31P MRS of the schizophrenic brain in vivo, J Comput Assist Tomogr 23(2) (1999), 272-275.
128. H. Fukuzako, T. Fukuzako, T. Hashiguchi, S. Kodama, M. Takigawa and T. Fujimoto, Changes in levels of phosphorus metabolites in temporal lobes of drug-naive schizophrenic patients, Am J Psychiatry 156(8) (1999), 1205-1208.
129. 31P chemical shift imaging study of medicated schizophrenic patients and healthy controls, Biol Psychiatry 45(6) (1999), 687-693.
130. 31P-MRS and CT studies, Eur Arch Psychiatry Clin Neurosci 250(4) (2000), 169-174.
131. 31P-MRS, J Affect Disord 22(4) (1991), 185-190.
132. 31P and 7Li magnetic resonance spectroscopy, J Affect Disord 27(1) (1993), 53-59.
133. 31P-MRS, Psychol Med 25(3) (1995), 557-566.
134. T. Kato, T. Inubushi and N. Kato, Magnetic resonance spectroscopy in affective disorders, J Neuropsychiatry Clin Neurosci 10(2) (1998), 133-147.
135. 31P NMR spectroscopy detects altered phospholipid metabolism in Alzheimer's disease, Can J Neurol Sci 13(4) (1998), 535-539.
136. 31P NMR profiles of Alzheimer's disease and multiple subcortical infarct dementia, Neurology 39(11) (1989), 1423-1427.
137. 31P magnetic resonance spectroscopy of Alzheimer disease, Alzheimer Dis Assoc Disord 10(1) (1996), 46-52.
138. 31P MRS study of autism: evidence for undersynthesis and increased degradation of brain membranes, Biol Psychiatry 33(11-12) (1993), 762-773.
139. C.M. Moore, J.D. Christensen, B. Lafer, M. Fava and P.F. Renshaw, Lower levels of nucleoside triphosphate in the basal ganglia of depressed subjects: a phosphorous-31 magnetic resonance spectroscopy study, Am J Psychiatry 154(1) (1997), 116-118.
140. A.J. Richardson, I.J. Cox, J. Sargentoni and B.K. Puri, Abnormal cerebral phospholipid metabolism in dyslexia indicated by phosphorus-31 magnetic resonance spectroscopy, NMR Biomed 10(7) (1997), 309-314.
141. 31P MRS study of patients with liver cirrhosis: progress towards a non-invasive assessment of disease severity, NMR Biomed 6(2) (1993), 168-172.
142. D.K. Menon, J. Sargentoni and S.D. Taylor-Robinson, et al., Effect of functional grade and etiology on in vivo hepatic phosphorus-31 magnetic resonance spectroscopy in cirrhosis: biochemical basis of spectral appearances, Hepatology 21(2) (1995), 417-427.
143. R. Jalan, J. Sargentoni and G.A. Coutts, et al., Hepatic phosphorus-31 magnetic resonance spectroscopy in primary biliary cirrhosis and its relation to prognostic models, Gut 39(1) (1996), 141-146.
144. 31P magnetic resonance spectroscopy and electron microscopy of the cirrhotic liver, Liver 17(4) (1997), 198-209.
145. K.K. Changani, R. Jalan and I.J. Cox, et al., Evidence for altered hepatic gluconeogenesis in patients with cirrhosis using in vivo 31-phosphorus magnetic resonance spectroscopy, Gut 49(4) (2001), 557-564.
146. 31P-MRS in diffuse hepatic disease: comparative studies with 99mTc-GSA], Nippon Igaku Hoshasen Gakkai Zasshi 60(8) (2000), 439-444.
147. 31P nuclear magnetic resonance spectroscopy, Clin Sci (Lond) 78(1) (1990), 33-38.
148. 31P magnetic resonance spectroscopy in chronic alcohol abusers, Gastroenterology 108(3) (1995), 776-788.
149. 31P MRS study, Alcohol Clin Exp Res 25(1) (2001), 89-97.
150. 31P magnetic resonance spectroscopy study, Alcohol Clin Exp Res 25(8) (2001), 1213-1220.
151. Y. Yamane, M. Umeda, T. O'Uchi, T. Mitsushima, K. Nakata and S. Nagataki, Phosphorus-31 nuclear magnetic resonance in vivo spectroscopy of human liver during hepatitis A virus infection, Dig Dis Sci 39(1) (1994), 33-38.
152. 31P MR spectroscopy to the histopathological grading of chronic hepatitis and response to therapy, Acta Radiol 39(3) (1998), 309-314.
153. 31Phosphorus magnetic resonance spectroscopy study in normal volunteers, Magn Reson Imaging 15(9) (1997), 1067-1077.
154. R. Smith, R.J. Newman, G.K. Radda, M. Stokes and A. Young, Hypophosphataemic osteomalacia and myopathy: studies with nuclear magnetic resonance spectroscopy, Clin Sci (Lond) 67(5) (1984), 505-509.
155. 31P NMR spectroscopy for evaluation of osteoporosis, Lancet 2(8549) (1987), 37-38.
156. J.P. Mattei, S. Confort-Gouny, J. Vion-Dury, H. Roux, J.P. Bisset and P.J. Cozzone, Study of bone mineralization using phosphorus 31 nuclear magnetic resonance spectroscopy. Results in a population of women with osteoporosis, Rev Rhum Engl Ed 62(2) (1995), 91-97.
157. 31P NMR spectroscopy reveals decreased PCr/Pi in patients with severe hypertrophic cardiomyopathy, Am J Cardiol 80(3A) (1997), 34A-40A.
158. 31P magnetic resonance spectroscopy in dilated cardiomyopathy and coronary artery disease. Altered cardiac high-energy phosphate metabolism in heart failure, Circulation 86(6) (1992), 1810-1818.
159. 31P magnetic resonance spectroscopy, Circulation 92(1) (1995), 15-23.
160. F. Sardanelli, F. Zandrino, G. Molinari, S. Cordone, L. Delfino and F. Levrero, Magnetic resonance spectroscopy of ischemic heart disease, Rays 24(1) (1999), 149-164.
161. 31P nuclear magnetic resonance evidence of skeletal muscle metabolic abnormalities in mitral stenosis, Am J Cardiol 78(5) (1996), 588-591.
162. 31P magnetic resonance spectroscopy study, Cardiovasc Res 52(1) (2001), 111-119.
163. R. Lodi, P.E. Hart and B. Rajagopalan, et al., Antioxidant treatment improves in vivo cardiac and skeletal muscle bioenergetics in patients with Friedreich's ataxia, Ann Neurol 49(5) (2001), 590-596.
164. 31P MR spectroscopy of the transplanted human kidney in situ shows altered metabolism in rejection and acute tubular necrosis, J Magn Reson Imaging 7(5) (1997), 858-864.
165. 31P MR spectroscopy, Acta Radiol 41(6) (2000), 634-641.
166. A. Zemtsov, L. Dixon and G. Cameron, Human in vivo phosphorus 31 magnetic resonance spectroscopy of psoriasis. A noninvasive tool to monitor response to treatment and to study pathophysiology of the disease, J Am Acad Dermatol 30(6) (1994), 959-965.
167. 31P NMR spectroscopy, J Biol Chem 262(31) (1987), 14875-14878.
168. 31P magnetic resonance spectroscopy: possible clinical significance, Mayo Clin Proc 63(12) (1988), 1199-1207.
169. P.F. Daly and J.S. Cohen, Magnetic resonance spectroscopy of tumors and potential in vivo clinical applications: a review, Cancer Res 49(4) (1989), 770-779.
170. W. Negendank, Studies of human tumors by MRS: a review, NMR Biomed 5(5) (1992), 303-324.
171. M.O. Leach, Magnetic resonance spectroscopy applied to clinical oncology, Technol Health Care 2(4) (1994), 235-246.
172. 31P magnetic resonance spectroscopy of large pediatric brain tumors, J Neurosurg 72(1) (1990), 65-70.
173. 31P magnetic resonance spectroscopy, Br J Cancer 61(3) (1990), 485-490.
174. 31P MR spectra from patients with hepatic lymphoma. A possible marker of liver infiltration and response to chemotherapy, Br J Cancer 63(6) (1991), 953-958.
175. 31P magnetic resonance spectroscopy study in non-Hodgkin's lymphoma, Br J Radiol 64(766) (1991), 923-928.
176. W.G. Negendank, K.A. Padavic-Shaller and C.W. Li, et al., Metabolic characterization of human non-Hodgkin's lymphomas in vivo with the use of proton-decoupled phosphorus magnetic resonance spectroscopy, Cancer Res 55(15) (1955), 3286-3294.
177. 31P nuclear magnetic resonance spectroscopy of osteosarcoma, Cancer Treat Res 62 (1993), 19-24.
178. H.J. Hoekstra, W.J. Boeve, R.L. Kamman and E.L. Mooyaart, Clinical applicability of human in vivo localized phosphorus-31 magnetic resonance spectroscopy of bone and soft tissue tumors, Ann Surg Oncol 1(6) (1994), 504-511.
179. W.G. Negendank, MR spectroscopy of musculoskeletal soft-tissue tumors, Magn Reson Imaging Clin N Am 3(4) (1995), 713-725.
180. C.W. Li, A.C. Kuesel and K.A. Padavic-Shaller, et al., Metabolic characterization of human soft tissue sarcomas in vivo and in vitro using proton-decoupled phosphorus magnetic resonance spectroscopy, Cancer Res 56(13) (1996), 2964-2972.
181. E. Furman, R. Margalit, P. Bendel, A. Horowitz and H. Degani, In vivo studies by magnetic resonance imaging and spectroscopy of the response to tamoxifen of MCF7 human breast cancer implanted in nude mice, Cancer Commun 3(9) (1991), 287-297.
182. T.E. Merchant, G.R. Thelissen, P.W. de Graaf, W. Den Otter and T. Glonek, Clinical magnetic resonance spectroscopy of human breast disease, Invest Radiol 26(12) (1991), 1053-1059.
183. 31P NMR spectra from human breast tumours: variations in phospholipid metabolism, Br J Cancer 63(4) (1991), 514-516.
184. C.J. Twelves, D.A. Porter and M. Lowry, et al., Phosphorus-31 metabolism of post-menopausal breast cancer studied in vivo by magnetic resonance spectroscopy, Br J Cancer 69(6) (1994), 1151-1156.
185. S.M. Ronen and M.O. Leach, Imaging biochemistry: applications to breast cancer, Breast Cancer Res 3(1) (2001), 36-40.
186. 31P magnetic resonance spectroscopy and biochemical analysis in vivo and in vitro. Cancer Res 51(19) (1991), 5160-5164.
187. 31P magnetic resonance spectroscopy in vivo, Clin Sci (Lond) 98(2) (2000), 167-174.
188. 31P NMR phospholipid characterization of intracranial tumors, Brain Res 649(1-2) (1994), 1-6.
189. P. Narayan, P. Jajodia and T. Kurhanewicz, et al., Characterization of prostate cancer, benign prostatic hyperplasia and normal prostates using transrectal 31phosphorus magnetic resonance spectroscopy: a preliminary report, J Urol 146(1) (1991), 66-74.
190. 31P magnetic resonance spectroscopy of focal hepatic malignancies, NMR Biomed 5(3) (1992), 114-120.
191. 31P-nuclear magnetic resonance studies of the effect of recombinant human interleukin 1 alpha on the bioenergetics of RIF-1 tumors, Cancer Res 49(22) (1989), 6379-6382.
192. 13C NMR studies, Proc Natl Acad Sci USA 86(14) (1989), 5585-5589.
193. 31P nuclear magnetic resonance spectroscopy: a review, Cancer Res 49(15) (1989), 4075-4085.
194. 31P magnetic resonance spectroscopy, Magn Reson Med 27(2) (1992), 226-237.
195. 31P NMR spectroscopy of human musculoskeletal tumors as a measure of response to chemotherapy, NMR Biomed 9(8) (1996), 347-358.
196. 31P MRS study, NMR Biomed 9(4) (1996), 165-172.
197. 31P magnetic resonance spectroscopy of (human) skeletal muscle, Proc Nutr Soc 58(4) (1999), 861-870.
198. X. Ravalec, N. Le Tallec, F. Carre, J.D. de Certaines and E. Le Rumeur, Improvement of muscular oxidative capacity by training is associated with slight acidosis and ATP depletion in exercising muscles, Muscle Nerve 19(3) (1996), 355-361.
199. M.R. Smith, Non-Hodgkin's lymphoma, in: Current Problems in Cancer, (Vol. XX), S.D. Williams, R. Goulet and G. Thomas, eds, St. Louis, MO: Mosby, 1966.
200. A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project, N Engl J Med 329(14) (1993), 987-994.
201. R. Ristamaki, H. Joensuu, K.O. Soderstrom and S. Jalkanen, CD44v6 expression in non-Hodgkin's lymphoma: an association with low histological grade and poor prognosis, J Pathol 176(3) (1995), 259-267.
202. P. Drillenburg, V.J. Wielenga and M.H. Kramer, et al., CD44 expression predicts disease outcome in localized large B cell lymphoma, Leukemia 13(9) (1999), 1448-1455.
203. H. Inagaki, S. Banno, A. Wakita, R. Ueda and T. Eimoto, Prognostic significance of CD44v6 in diffuse large B-cell lymphoma, Mod Pathol 12(5) (1999), 546-552.
204. P. Korkolopoulou, M.K. Angelopoulou and F. Kontopidou, et al., Prognostic implications of proliferating cell nuclear antigen (PCNA), AgNORs and p53 in non-Hodgkin's lymphomas, Leuk Lymphoma 30(5-6) (1998), 625-636.
205. M.B. Moller, A.M. Gerdes, K. Skjodt, L.S. Mortensen and N.T. Pedersen, Disrupted p53 function as predictor of treatment failure and poor prognosis in B-and T-cell non-Hodgkin's lymphoma, Clin Cancer Res 5(5) (1999), 1085-1091.
206. R. Stauder, W. Eisterer, J. Thaler and U. Gunthert, CD44 variant isoforms in non-Hodgkin's lymphoma: a new independent prognostic factor, Blood 85(10) (1995), 2885-2899.
207. A.A. Alizadeh, M.B. Eisen and R.E. Davis, et al., Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling, Nature 403(6769) (2000), 503-511.
208. 31P-NMR studies of a human tumour in situ, Lancet 1(8339) (1983), 1435-1436.
209. 31P spectroscopy of the human head, J Magn Reson B 103(2) (1994), 103-114.
210. F. Hirata, S. Toyoshima, J. Axelrod and M.J. Waxdal, Phospholipid methylation: a biochemical signal modulating lymphocyte mitogenesis, Proc Natl Acad Sci USA 77(2) (1980), 862-865.
211. Y. Niwa and S. Taniguchi, Phospholipid base exchange in human leukocyte membranes: quantitation and correlation with other phospholipid biosynthetic pathways, Arch Biochem Biophys 250(2) (1986), 345-357.
212. Z. Kiss, K.S. Crilly and W.H. Anderson, Carcinogens stimulate phosphorylation of ethanolamine derived from increased hydrolysis of phosphatidylethanolamine in C3H/101/2 fibroblasts, FEBS Lett 336(1) (1993), 115-118.
213. Z. Kiss, M. Tomono and W.B. Anderson, Phorbol ester selectively stimulates the phospholipase D-mediated hydrolysis of phosphatidylethanolamine in multidrug-resistant MCF-7 human breast carcinoma cells, Biochem J 302(Pt 3) (1994), 649-654.
214. 31P NMR measurements of the effects of unsaturated fatty acids on cellular phospholipid metabolism, Magn Reson Med 35(4) (1996), 481-488.
215. 31P nuclear magnetic resonance spectroscopy in vitro and by administration of 14C-radiolabelled compounds in vivo, Biochim Biophys Acta 1181(2) (1993), 111-121.
216. 31P magnetic resonance spectroscopy in vivo and in vitro, Br J Cancer 69(4) (1994), 633-640.
217. 31P MR spectroscopy study, Strahlenther Onkol 177(4) (2001), 212-219.
218. 31P MR spectral alterations in human hepatic tumours, NMR Biomed 11(7) (1998), 354-359.
219. R. Dahiya, B. Boyle, H.D. Park, J. Kurhanewicz, J.M. Macdonald and P. Narayan, 13-cis-retinoic acid-mediated growth inhibition of DU-145 human prostate cancer cells, Biochem Mol Biol Int 32(1) (1994), 1-12.
220. 31P MRS study, Br J Cancer 67(5) (1993), 1145-1153.
221. 31P magnetic resonance spectroscopy of the human liver, NMR Biomed 1(4) (1989), 184-189.
222. 31P NMR spectroscopy, NMR Biomed 6(4) (1993), 254-263.
223. F. Podo, Tumour phospholipid metabolism, NMR Biomed 12(7) (1999), 413-439.
224. E.O. Aboagye and Z.M. Bhujwalla, Malignant transformation alters membrane choline phospholipid metabolism of human mammary epithelial cells, Cancer Res 59(1) (1999), 80-84.
225. R.M. Dixon, NMR studies of phospholipid metabolism in hepatic lymphoma, NMR Biomed 11(7) (1998), 370-379.
226. L. Bogin, M.Z. Papa, S. Polak-Charcon and H. Degani, TNF-induced modulations of phospholipid metabolism in human breast cancer cells, Biochim Biophys Acta 1392(2-3) (1998), 217-232.
227. Y.L. Ting, D. Sherr and H. Degani, Variations in energy and phospholipid metabolism in normal and cancer human mammary epithelial cells, Anticancer Res 16(3B) (1996), 1381-1388.
228. 31P magnetic resonance spectroscopy study, Br J Cancer 67(6) (1993), 1303-1309.
229. J. Lloveras, M. Hamza, H. Chap and L. Douste-Blazy, Action of hemicholinium-3 on phospholipid metabolism in Krebs II ascites cells, Biochem Pharmacol 34(22) (1985), 3987-3993.
230. 31P NMR studies of cultured human tumor cells. Influence of pH on phospholipid metabolite levels and the detection of cytidine 5′-diphosphate choline, NMR Biomed 3(2) (1990), 78-89.
231. 31P MRS in vivo in human cancer: implications for experimental models and clinical studies, Anticancer Res 16(3B) (1996), 1539-1544.
232. J.L. Evelhoch, R.J. Gillies and G.S. Karczmar, et al., Applications of magnetic resonance in model systems: cancer therapeutics, Neoplasia 2(1-2) (2000), 152-165.